Other studies confirmed that the expression of TRIB3 is greater in solid tumors such as colorectal cancer, breast cancer, lung cancer, ovarian cancer, melanoma, liver cancer, and leukemia (Wennemers et al., 2011; Salazar et al., 2015; Hua et al., 2019; Zhang X. et al., 2019; Wang et al., 2020; Zhu et al., 2020), suggesting that TRIB3 is a potential target for cancer treatment. Here, TRIB3 is linked to cancer.